CHGCY (Chugai Pharmaceutical Co) Research & Development: $1,245 Mil (TTM As of Mar. 2026)


CHGCY Chugai Pharmaceutical Co Ltd CHGCY
92 GF Score
Price $22.99
GF Value $24.27
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Research & Development?

Chugai Pharmaceutical Co CHGCY +0.13% 92 Research & Development is $1,245 Mil as of Mar. 2026. GuruFocus rates CHGCY with a GF Score™ of 92/100 and a GF Value™ of $24.27 (Fairly Valued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Chugai Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was $264 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $1,245 Mil.

Chugai Pharmaceutical Co  (OTCPK:CHGCY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Chugai Pharmaceutical Co Research & Development Related Terms

Chugai Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co Research & Development Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,206.15 1,109.04 1,214.52 1,179.60 1,203.21

Chugai Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 274.57 316.05 328.69 336.12 263.97
CHGCY
92GF Score
Chugai Pharmaceutical Co Ltd CHGCY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chugai Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,245 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1,245 Mil mean?
Chugai Pharmaceutical Co (CHGCY) has a Research & Development of $1,245 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's Research & Development too high?
Chugai Pharmaceutical Co's current Research & Development is $1,245 Mil. Overall, Chugai Pharmaceutical Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Research & Development compare to LLY and JNJ?
Chugai Pharmaceutical Co's Research & Development of $1,245 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Research & Development is $1,245 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCY) is currently considered Fairly Valued. The stock's GF Value™ is $24.27, compared to a current price of $22.99 — trading 5.3% below its estimated fair value. The current Research & Development is $1,245 Mil. Chugai Pharmaceutical Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCY), the current Research & Development is $1,245 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (CHGCY) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of $22.99 is trading 5.3% below its estimated GF Value™ of $24.27. GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.

Key valuation signals for CHGCY:

  • Research & Development: $1,245 Mil
  • GF Value™: $24.27 vs. price of $22.99 (5.3% below fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the CHGCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
92GF Score

Get the complete analysis for CHGCY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.99
Price
$24.27
GF Value